coronado biosciences inc (CNDO) Key Developments
Coronado Biosciences, Inc.(NasdaqCM:CNDO) dropped from Russell 2000 Index
Jun 30 14
Coronado Biosciences, Inc. will be removed from the Russell 2000 Index.
Coronado Biosciences, Inc.(NasdaqCM:CNDO) dropped from Russell 3000 Index
Jun 30 14
Coronado Biosciences, Inc. will be removed from the Russell 3000 Index.
Coronado Biosciences Reports Topline Results From Investigator Initiated Pilot Study of TSO in Adults With Autism Spectrum Disorder
Jun 26 14
Coronado Biosciences, Inc. announced the completion of pilot study of oral TSO (Trichuris suis ova or CNDO-201) for adults with Autism Spectrum Disorder (ASD). The study was a double-blind, randomized, placebo-controlled, cross-over study and enrolled 10 high functioning adult autism spectrum disorder patients who were able to give informed consent to participate in the study, and who had a history of allergies and/or a family history of immune-inflammatory illness. They were treated for 12 weeks with either TSO or placebo, followed by a 4-week washout phase and then 12 weeks of placebo or TSO. The TSO dosage used in the study was 2,500 ova once every two weeks. While none of the measures reached statistical significance, benefits with TSO treatment (over placebo) were observed in several subscales, including the Montefiore-Einstein Rigidity Scale (MERS), ABC Irritability, RBS-R Sameness, and RBS-R Restricted Behavior. TSO was well-tolerated; no patient discontinued due to an adverse event (or due to tolerability issues), and 9 of 10 patients completed the full 26 week treatment period.
Coronado Biosciences, Inc. Appoints EisnerAmper LLP as its Independent Registered Public Accounting Firm
Jun 17 14
Coronado Biosciences, Inc. ratified the appointment of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2014 at its 2014 annual meeting of stockholders held on June 16, 2014.
Coronado Biosciences Initiates Clinical Study of TSO in Pediatric Patients with Autism Spectrum Disorder
May 14 14
Coronado Biosciences, Inc. announced that it has initiated a Phase 2a clinical trial of TSO (Trichuris suis ova or CNDO-201) for the treatment of pediatric patients with autism spectrum disorder (ASD) at multiple centers in the United States. The study is a randomized, double-blind, placebo-controlled crossover study designed to evaluate the safety and efficacy of TSO in pediatric patients with ASD. Approximately 20 ASD patients in the age range of 5 to 17 will be enrolled and randomized to receive either TSO or placebo once every 2 weeks, for 16 weeks, followed with a 4 week washout and the opposite treatment for 16 weeks. The primary endpoint for the study is Aberrant Behavior Checklist -- Irritability subscale (ABC-I) and the key secondary endpoint is Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders (CYBOCS-PDD).